Ascendis Pharma A/S (ASND)
253.38
+1.43
(+0.57%)
USD |
NASDAQ |
Aug 25, 16:00
253.38
0.00 (0.00%)
After-Hours: 18:36
Ascendis Pharma EPS Diluted (Quarterly) : 3.522 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.522 |
| March 31, 2026 | 11.41 |
| December 31, 2025 | -0.6364 |
| September 30, 2025 | -1.173 |
| June 30, 2025 | -0.7285 |
| March 31, 2025 | -1.659 |
| December 31, 2024 | -0.6857 |
| September 30, 2024 | -1.894 |
| June 30, 2024 | -2.053 |
| March 31, 2024 | -2.500 |
| December 31, 2023 | -1.650 |
| September 30, 2023 | -3.136 |
| June 30, 2023 | -2.351 |
| March 31, 2023 | -2.122 |
| December 31, 2022 | -3.779 |
| September 30, 2022 | -3.046 |
| June 30, 2022 | -1.551 |
| March 31, 2022 | -2.482 |
| December 31, 2021 | -2.135 |
| September 30, 2021 | -1.733 |
| June 30, 2021 | -3.008 |
| March 31, 2021 | -1.407 |
| December 31, 2020 | -3.082 |
| September 30, 2020 | -2.699 |
| June 30, 2020 | -2.169 |
| Date | Value |
|---|---|
| March 31, 2020 | -1.454 |
| December 31, 2019 | -1.854 |
| September 30, 2019 | -0.5867 |
| June 30, 2019 | -1.403 |
| March 31, 2019 | -1.404 |
| December 31, 2018 | -0.8672 |
| September 30, 2018 | -0.9432 |
| June 30, 2018 | -0.655 |
| March 31, 2018 | -1.315 |
| December 31, 2017 | -1.083 |
| September 30, 2017 | -1.222 |
| June 30, 2017 | -1.035 |
| March 31, 2017 | -0.8313 |
| December 31, 2016 | -0.5496 |
| September 30, 2016 | -0.8036 |
| June 30, 2016 | -0.5984 |
| March 31, 2016 | -0.9041 |
| December 31, 2015 | -0.5225 |
| September 30, 2015 | -0.3335 |
| June 30, 2015 | -0.6969 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | -0.2623 |
| September 30, 2014 | -0.106 |
| June 30, 2014 | -0.123 |
| March 31, 2014 | -0.0685 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Evaxion AS | -0.4464 |
| Genmab A/S | 0.4903 |
| Zealand Pharma A/S | 8.610 |
| Cellectis SA | -0.2165 |
| BioMarin Pharmaceutical, Inc. | 0.2302 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 240.65M |
| Revenue (Quarterly) | 394.49M |
| Total Expenses (Quarterly) | 153.84M |
| Enterprise Value | 16.13B |
| Gross Profit Margin (Quarterly) | 90.64% |
| Profit Margin (Quarterly) | 61.00% |
| Earnings Yield | 5.18% |
| Operating Earnings Yield | 0.78% |
| Normalized Earnings Yield | 5.180 |